The agent, CTC-96, also known as Doxovir, was developed by Redox Pharmaceutical. CTC-96’s novel antiviral mechanism has demonstrated efficacy against multiple viral infections in preclinical studies. CTC-96 has anti-inflammatory properties but it is a nonsteroidal compound, an important safety advantage for an ocular drug.
Samuel Reich, executive vice president of ophthalmics at Opko, said: “We look forward to initiating Phase II trials assessing CTC-96 for the treatment of viral conjunctivitis in the coming months.”